Back
Fulcrum Therapeutics Stock Predictions
Data Just Made Palantir Worth $200B - Is This #1 Software Company Next?
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
24
FULC
Fulcrum Therapeutics
Last Price:
$3.69
Seasonality Move:
-28.47%
7 Day Trial
ALL ACCESS PASS
$
7
Apple's Space Move Could Send This Pre-IPO Stock Soaring
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.Fulcrum Therapeutics Stock Forecast
-
Is Fulcrum Therapeutics Stock Undervalued?The current Fulcrum Therapeutics [FULC] share price is $3.69. The Score for FULC is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.
-
FULC is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
Will Fulcrum Therapeutics Stock Go Up Next Year?
Data Unavailable
Fulcrum Therapeutics Stock Rating
Data Unavailable
Fulcrum Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
fulcrumtx.com
52-Week Data
52-Week High:
13.70
52-Week Low:
2.86
Prediction Charts
Market Cap:
199M
Price in USD:
3.69
Volume:
848.4K
Beta:
2.23
Technical Analysis
SMA50:
4.16
SMA100:
3.80
SMA200:
5.75
52-Wk Change:
-59.41%
Stock Predictions
-
Is Fulcrum Therapeutics stock public?Yes, Fulcrum Therapeutics is a publicly traded company.
-
What is the Fulcrum Therapeutics stock quote today?The Fulcrum Therapeutics stock price is 3.69 USD today.
-
How to buy Fulcrum Therapeutics stock online?You can buy Fulcrum Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Jan-28 | 4.10 | 4.05 | 4.13 | 3.86 |
| Jan-29 | 4.05 | 4.08 | 4.13 | 3.93 |
| Jan-30 | 4.14 | 4.18 | 4.19 | 4.02 |
| Jan-31 | 4.18 | 3.96 | 4.24 | 3.93 |
| Feb-3 | 3.83 | 3.81 | 3.94 | 3.78 |
| Feb-4 | 3.79 | 3.82 | 3.89 | 3.67 |
| Feb-5 | 3.85 | 3.91 | 3.94 | 3.83 |
| Feb-6 | 3.92 | 3.83 | 3.93 | 3.81 |
| Feb-7 | 3.83 | 3.69 | 3.86 | 3.66 |
| Feb-10 | 3.68 | 3.63 | 3.72 | 3.56 |
| Feb-11 | 3.56 | 3.44 | 3.62 | 3.42 |
| Feb-12 | 3.37 | 3.56 | 3.59 | 3.37 |
| Feb-13 | 3.61 | 3.71 | 3.71 | 3.52 |
| Feb-14 | 3.76 | 3.69 | 3.94 | 3.63 |
Fulcrum Therapeutics Earnings
Data Unavailable
Fulcrum Therapeutics Forecast Revenue Growth
Data Unavailable
-
Analysts estimate an earnings decrease this quarter of $0.13 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.94 per share, and a decrease next year of $0.07 per share.
* Fulcrum Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.